Castle Biosciences, Inc.

Castle Biosciences Beats on EPS, Stock Up 3.41%

Castle Biosciences reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising 3.41%. However, there was no revenue reported or guidance provided, leaving investors with limited insights into future performance. The significant EPS surprise may indicate better cost management or operational efficiencies.